



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Operations Office

TO: Primary Clinical Research Associates

FROM: Sara Braun
Research Protocol Specialist III

DATE: March 26, 2010

SUBJECT: N0272, Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma

The Fax Supply Order Form has been updated to reflect Biospecimen Accessioning Processing rather than Mayo Medical Laboratory.

If you have any questions, please feel free to contact me at 507/538-8226.

Thank you.